Fig 5. Nrp1 protein expression is down regulated in recurrent GBM following bevacizumab treatment.

(A-F); Immunohistochemistry was performed with anti-Nrp1 antibodies using matched human GBM surgical resections collected prior to bevacizumab treatment (A-C) and after bevacizumab treatment (D-F). Note that Nrp1 protein levels are diminished in GBM cells and in intratumoral blood vessels in recurrent tumors following bevacizumab therapy.